Your browser doesn't support javascript.
loading
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Jaiswal, Ashvin R; Liu, Arthur J; Pudakalakatti, Shivanand; Dutta, Prasanta; Jayaprakash, Priyamvada; Bartkowiak, Todd; Ager, Casey R; Wang, Zhi-Qiang; Reuben, Alexandre; Cooper, Zachary A; Ivan, Cristina; Ju, Zhenlin; Nwajei, Felix; Wang, Jing; Davies, Michael A; Davis, R Eric; Wargo, Jennifer A; Bhattacharya, Pratip K; Hong, David S; Curran, Michael A.
Affiliation
  • Jaiswal AR; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Liu AJ; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Pudakalakatti S; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dutta P; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Jayaprakash P; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bartkowiak T; Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ager CR; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang ZQ; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Reuben A; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Cooper ZA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Ivan C; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Ju Z; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nwajei F; Departments of Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wang J; Departments of Genomic Medicine and Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Davies MA; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Davis RE; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wargo JA; Department of Symptom Research, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bhattacharya PK; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Hong DS; MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.
  • Curran MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Immunol Res ; 8(11): 1365-1380, 2020 11.
Article in En | MEDLINE | ID: mdl-32917656
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / Immunotherapy Limits: Animals / Humans / Male Language: En Journal: Cancer Immunol Res Year: 2020 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Melanoma, Experimental / Immunotherapy Limits: Animals / Humans / Male Language: En Journal: Cancer Immunol Res Year: 2020 Document type: Article Country of publication: United States